This clinical trial is testing an siRNA therapy for Parkinson’s disease.
The siRNA (small interfering RNA) therapy is designed to lower the levels of α-synuclein, a protein linked to the progression of Parkinson’s. By reducing the levels of this protein, researchers hope to slow the progression of the disease.
The clinical trial will assess the effects of the siRNA therapy on the body, how the body processes it, and the best dose level.
If you are interested in taking part in this clinical trial, email Jim Howley, Global Lead Patient Advocacy and Engagement, at Prevail.Patients@lilly.com or speak to your healthcare team.
To join the Parkinson’s siRNA (small interfering RNA) therapy clinical trial, you need to meet these requirements:
siRNA (small interfering RNA) is a new type of therapy designed to reduce the production of specific proteins in the body. By targeting harmful proteins, it may help protect cells and slow the progression of certain diseases.
How it works: siRNA works by interrupting the process that makes proteins in cells. By targeting certain proteins, it can stop their production or reduce their levels.
Why it’s being tested for Parkinson’s: In diseases like Parkinson’s, certain proteins can build up in the brain and cause damage. siRNA therapy aims to reduce the levels of these harmful proteins, potentially slowing disease progression.
This siRNA therapy targets α-synuclein, a protein linked to the progression of Parkinson’s.
Targeting α-synuclein: α-synuclein is a protein that can clump together in the brain and damage nerve cells, leading to Parkinson’s symptoms.
Reducing α-synuclein: This siRNA therapy is designed to work by lowering the levels of α-synuclein in the brain, which may help protect nerve cells and slow the progression of the disease.
This siRNA therapy is a new approach designed to address the underlying cause of Parkinson’s, offering a different approach from current treatments.
Current treatments: Current treatments focus on managing symptoms. While they can help some people with their symptoms, these medicines often lose effectiveness as the disease progresses and may cause side effects. They don’t target the root cause of Parkinson’s.
How siRNA therapy works: siRNA therapy focuses on lowering α-synuclein levels, a protein linked to disease progression. Scientists hope it will provide long-term benefits beyond symptom management.
This clinical trial is testing an siRNA therapy for people with Parkinson’s. The siRNA therapy will be given through an injection into the lower spine.
The trial is placebo-controlled, meaning some participants will receive the siRNA therapy, while others will receive a placebo. Participants will be randomly assigned to the treatment, with a 3 in 4 chance of receiving the siRNA therapy, and a 1 in 4 chance of receiving the placebo.
The trial will assess how the siRNA therapy affects the body, how the body processes it, and the best dose level.
This clinical trial is testing a new siRNA therapy for Parkinson’s. At this stage, this siRNA therapy has no known health benefits.
By participating in the clinical trial, the data collected from you may help researchers and doctors learn more about siRNA therapy and its potential to benefit patients with Parkinson’s or similar conditions in the future.
To find your nearest center for our siRNA therapy clinical trial for sporadic Parkinson’s, please visit ClinicalTrials.gov.
There, you can see detailed information about where the clinical trial is taking place.
